TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03754049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
Study: NCT02940002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone/calcipotriene
Description: Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Study: NCT02556476

Intervention type: PROCEDURE
Intervention: mechanical ventilation
Description: ventilator support for the patients presenting with acute respiratory failure

Intervention type: PROCEDURE
Intervention: neuromuscular blockade
Description: paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS

Intervention type: PROCEDURE
Intervention: renal replacement therapy
Description: the procedures used to treat acute kidney injury

Intervention type: PROCEDURE
Intervention: non-invasive ventilation
Description: Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
Study: NCT00432601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: type of decision aid
Description: We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: type of decision aid
Description: We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
Study: NCT00829985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycerinated German Cockroach Allergenic Extract
Description: Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
Study: NCT04426760

Intervention type: PROCEDURE
Intervention: Transcervical resection of fibroids
Description: Transcervical resection of fibroids

Intervention type: PROCEDURE
Intervention: Myomectomy per laparoscopy or laparotomy
Description: Myomectomy per laparoscopy or laparotomy
Study: NCT03575481

Intervention type: DIAGNOSTIC_TEST
Intervention: The RAT and The TST
Description: The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
Study: NCT03606070

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-MRI
Description: * a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).
Study: NCT02401295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT02274038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline 18F-thymidine (FLT) PET/CT
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
Study: NCT01766700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 no calorie beverages per day
Description: Weekly and monthly lifestyle weight loss/maintenance classes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 water beverages per day
Description: Weekly and monthly lifestyle weight loss/maintenance classes.
Study: NCT04508387

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group HH (heated-humidified)
Description: Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
Study: NCT02948101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CSF1 Monoclonal Antibody PD-0360324
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03034668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CS16-003 Full dose
Description: 350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CS16-003 Half dose
Description: 175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin: 350 mg
Study: NCT04508387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group HH (heated-humidified)
Description: Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
Study: NCT00862251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin 40 mg or atorvastatin 20 mg
Description: simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: rosuvastatin 10 mg tablets, taken once daily for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 10 mg or simvastatin 20 mg
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin 10 mg or simvastatin 20 mg
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 10 mg or simvastatin 20 mg
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
Study: NCT04609696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 1
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study: NCT02547727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
Study: NCT01555086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited pelvic Lymphadenectomy
Description: approximately 10-14 lymph nodes are removed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended pelvic Lymphadenectomy
Description: approximately 20 lymph nodes are removed
Study: NCT00066001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metronidazole
Description: antibiotic that is particularly effective against Gram negative bacterial species
Study: NCT00539110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolipidem
Description: zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
Study: NCT04609696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 1
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 1
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 2
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study: NCT02241096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
Study: NCT03744000

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
Study: NCT01070147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Asthma Management System
Description: The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
Study: NCT03472443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
Study: NCT03621345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham block
Description: A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
Study: NCT00056498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal
Description: Risperdal 4 mg per day for 16 weeks
Study: NCT00539110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
Study: NCT01683474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus MedTech Aortic Valve Prosthesis
Description: Percutaneous implantation of aortic valve of Venus-A
Study: NCT01817985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5816
Study: NCT02547727

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
Study: NCT02132494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT04609696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 2
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 2
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study: NCT02613754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: See arm description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: See arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: See arm description
Study: NCT01725529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon-alpha (PegIFNα-2a)
Description: PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha (PegIFNα-2a)
Description: PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha (PegIFNα-2a)
Description: PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken orally with food once-daily for 48 weeks.
Study: NCT02082392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance or treatment of no intended therapeutic value in a pill form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance or treatment of no intended therapeutic value in a pill form.
Study: NCT05119946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide prevention video
Description: The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard suicide treatment
Description: The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard suicide treatment
Description: The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
Study: NCT00207090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
Study: NCT00833586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine HCl 250mg tablets
Description: 1 x 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® 250 mg Tablets
Description: 1 x 250 mg
Study: NCT06510634

Intervention type: OTHER
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.

Intervention type: OTHER
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.